Moreno Evelyn V Sells 20,593 Shares of Danaher Co. (NYSE:DHR)

Moreno Evelyn V reduced its holdings in shares of Danaher Co. (NYSE:DHR) by 59.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,840 shares of the conglomerate’s stock after selling 20,593 shares during the quarter. Danaher makes up about 1.5% of Moreno Evelyn V’s holdings, making the stock its 16th largest position. Moreno Evelyn V’s holdings in Danaher were worth $3,202,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. BKM Wealth Management LLC bought a new stake in Danaher during the fourth quarter worth $27,000. Wetzel Investment Advisors Inc. purchased a new stake in Danaher in the fourth quarter worth $29,000. Rakuten Securities Inc. purchased a new stake in Danaher in the fourth quarter worth $36,000. Financial Connections Group Inc. purchased a new stake in Danaher in the fourth quarter worth $41,000. Finally, Frazier Financial Advisors LLC purchased a new stake in Danaher in the fourth quarter worth $44,000. 79.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on DHR. Robert W. Baird raised their target price on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Citigroup raised their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Bank of America raised their target price on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. KeyCorp raised their target price on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Finally, HSBC upgraded Danaher from a “hold” rating to a “buy” rating and lifted their price target for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.31.

Danaher Price Performance

NYSE:DHR traded down $1.94 during trading hours on Thursday, hitting $265.25. 1,075,007 shares of the company’s stock traded hands, compared to its average volume of 2,680,774. The firm has a market cap of $196.47 billion, a P/E ratio of 45.31, a P/E/G ratio of 4.08 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $268.98. The business’s fifty day simple moving average is $249.54 and its two-hundred day simple moving average is $238.04. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter last year, the company earned $2.36 earnings per share. On average, research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.41%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insiders Place Their Bets

In other Danaher news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Danaher news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The disclosure for this sale can be found here. Insiders sold a total of 172,540 shares of company stock valued at $43,523,481 over the last 90 days. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.